We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
- Abstract
The article presents a study which examines the ability of sorafenib to improve progression-free survival (PFS) in patients suffering with locally advanced or metastatic, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Sorafenib is a multikinase inhibitor and it prevents the molecular signals which play a role in the pathogenesis of thyroid cancer and DTC.
- Publication
BMC Cancer, 2011, Vol 11, Issue 1, p349
- ISSN
1471-2407
- Publication type
Academic Journal
- DOI
10.1186/1471-2407-11-349